In homogeneous catalysis, the catalyst is in the same phase as the reactant. The number of collisions between reactants and catalyst is at a maximum.In a patent, 1055361-35-7, name is 4-(4-((2,4-Dioxothiazolidin-5-ylidene)methyl)-2-methoxyphenoxy)-3-(trifluoromethyl)benzonitrile, introducing its new discovery. HPLC of Formula: C19H11F3N2O4S
AMINO-ETHYL-AMINO-ARYL (AEAA) COMPOUNDS AND THEIR USE
The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain amino-ethyl-amino-aryl (AEAA) compounds which, inter alia, inhibit protein kinase D (PKD) (e.g., PKD1, PKD2, PKD3). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit PKD, and in the treatment of diseases and conditions that are mediated by PKD, that are ameliorated by the inhibition of PKD, etc., including proliferative conditions such as cancer, etc.
If you are interested in 1055361-35-7, you can contact me at any time and look forward to more communication. HPLC of Formula: C19H11F3N2O4S
Reference£º
Quinuclidine – Wikipedia,
Quinuclidine | C7H863N | ChemSpider